Current Assets
Cash & Equivalents
Boston Scientific Cash & Equivalents decreased by 11.9% to $850.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 146.4%, from $345.00M to $850.00M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 45.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2012
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase suggests strong liquidity and potential for investment, while a decrease may indicate heavy capital expenditure or debt repayment.
Detailed definition
This represents the most liquid assets held by the company, including currency, demand deposits, and short-term investme...
Peer comparison
Standard across all industries; peers in medical devices typically maintain significant cash for R&D cycles.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $296.00M | $410.00M | $293.00M | $299.00M | $240.00M | $242.00M | $256.00M | $140.00M | $409.00M | $382.00M | $411.00M | $384.00M | $793.00M | $803.00M | $364.00M | $345.00M | $388.00M | $893.00M | $965.00M | $850.00M |
| QoQ Change | — | +38.5% | -28.5% | +2.0% | -19.7% | +0.8% | +5.8% | -45.3% | +192.1% | -6.6% | +7.6% | -6.6% | +106.5% | +1.3% | -54.7% | -5.2% | +12.5% | +130.2% | +8.1% | -11.9% |
| YoY Change | — | — | — | — | -18.9% | -41.0% | -12.6% | -53.2% | +70.4% | +57.9% | +60.5% | +174.3% | +93.9% | +110.2% | -11.4% | -10.2% | -51.1% | +11.2% | +165.1% | +146.4% |
Range$140.00M – $965.00M
CAGR+24.9%
Avg YoY Growth+43.2%
Median YoY Growth+34.5%
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Boston Scientific's cash & equivalents?
- Boston Scientific (BSX) reported cash & equivalents of $850.00M in Q1 2026.
- How has Boston Scientific's cash & equivalents changed year-over-year?
- Boston Scientific's cash & equivalents increased by 146.4% year-over-year, from $345.00M to $850.00M.
- What is the long-term trend for Boston Scientific's cash & equivalents?
- Over 5 years (2020 to 2025), Boston Scientific's cash & equivalents has grown at a 45.1% compound annual growth rate (CAGR), from $150.00M to $965.00M.
- What does cash & equivalents mean?
- The total value of cash and highly liquid investments that can be accessed immediately.